10.1 ICU Glycemic Control & Severe Hypoglycemia
Key Takeaways
The NICE-SUGAR trial (2009) found higher 90-day mortality with a glucose target of 81 to 108 mg/dL (27.5%) than with a target of 180 mg/dL or less (24.9%), driven by severe hypoglycemia.
The 2026 Surviving Sepsis Campaign recommends starting insulin at a glucose level of 180 mg/dL or more, aiming for roughly 144 to 180 mg/dL.
Octreotide 50 to 100 micrograms subcutaneously every 6 to 12 hours suppresses the insulin release that causes recurrent hypoglycemia after sulfonylurea overdose.
Severe hypoglycemia with no intravenous access is treated with glucagon 1 mg intramuscularly, which requires hepatic glycogen and fails in alcoholic or fasting liver disease.
Sustained glucose below about 40 mg/dL causes neuroglycopenia and can produce permanent injury; relative hypoglycemia also carries risk in patients whose usual glucose runs high.
Stress Hyperglycemia and Why Tight Control Failed
Critical illness raises glucose through counterregulatory hormones (cortisol, catecholamines, glucagon, growth hormone), inflammatory cytokines that cause insulin resistance, and iatrogenic loads from dextrose, nutrition, and corticosteroids. Hyperglycemia is associated with infection, impaired neutrophil function, osmotic diuresis, and worse outcomes, which drove early enthusiasm for normalizing glucose.
| Trial | Design | Result |
|---|---|---|
| Leuven I (2001) | Surgical ICU, target 80–110 mg/dL | Lower mortality in a single center with high dextrose feeding |
| Leuven II (2006) | Medical ICU | No overall mortality benefit; more hypoglycemia |
| NICE-SUGAR (2009) | 6,104 patients, target 81–108 vs 180 or less mg/dL | Higher 90-day mortality with intensive control (27.5% vs 24.9%), with severe hypoglycemia in 6.8% vs 0.5% |
| TGC-Fast (2023) | Tight control with early parenteral nutrition withheld | No benefit from tight control |
The lesson is that iatrogenic hypoglycemia and glucose variability cause harm that outweighs the benefit of normal numbers.
Current Targets
- Start insulin when glucose reaches 180 mg/dL or more, which the 2026 Surviving Sepsis Campaign recommends for sepsis and septic shock.
- Target range: roughly 140 to 180 mg/dL (the SSC describes 144 to 180 mg/dL). Some guidelines accept 110 to 180 mg/dL in selected patients, but targets below about 110 mg/dL are not recommended.
- Use a validated IV insulin infusion protocol with frequent monitoring (every 1 to 2 hours until stable, then every 2 to 4 hours).
- Avoid variability: hold or reduce insulin when nutrition is interrupted, and remember that stopping a steroid or starting dialysis against a low-glucose bath changes requirements abruptly.
- Measurement matters: point-of-care capillary glucose is unreliable in shock, with edema, anemia or polycythemia, and on vasopressors. Confirm extreme or discordant values with an arterial or venous sample on a blood gas analyzer or laboratory assay.
- Subcutaneous basal-bolus insulin replaces an infusion when the patient is stable and eating; sliding-scale-only regimens are inadequate.
Severe Hypoglycemia
Definition: Level 1 is glucose below 70 mg/dL, Level 2 below 54 mg/dL, and Level 3 is any severe event with altered mental status or physical impairment. Below about 40 mg/dL, neuroglycopenia produces confusion, seizures, focal deficits, or coma, and prolonged episodes cause permanent injury. Autonomic warning symptoms are blunted by beta-blockers, sedation, and recurrent hypoglycemia.
Causes in the ICU
| Category | Examples |
|---|---|
| Iatrogenic | Insulin or sulfonylurea dosing errors, interrupted nutrition during an insulin infusion, dialysis with low-glucose dialysate, insulin ordered for hyperkalemia |
| Drugs | Sulfonylureas and meglitinides, quinine, quinolones (rarely), pentamidine, beta-blockers masking symptoms, tramadol |
| Organ failure | Acute liver failure (loss of gluconeogenesis and glycogen), kidney failure (reduced insulin clearance), heart failure, sepsis (late) |
| Endocrine | Adrenal insufficiency, pituitary failure, insulinoma, insulin autoimmune syndrome |
| Other | Alcohol with depleted glycogen, starvation, post-gastric-bypass hypoglycemia, large tumors producing IGF-2, hypoglycemia after glucose-lowering overdoses |
Treatment
- Give glucose: 25 g of dextrose 50% IV (50 mL), or 10% dextrose in 100 to 250 mL boluses, which is preferred for peripheral veins and in children. Recheck in 15 minutes and repeat as needed.
- No IV access: glucagon 1 mg IM or SC. It mobilizes hepatic glycogen, so it fails in alcoholic, fasting, or advanced liver disease, and causes vomiting.
- Continuous infusion: start dextrose 10% (occasionally 20% through a central line) when hypoglycemia recurs, and feed the patient.
- Sulfonylurea or meglitinide overdose: give dextrose plus octreotide 50 to 100 micrograms subcutaneously every 6 to 12 hours, which suppresses pancreatic insulin release and prevents the rebound hypoglycemia that dextrose alone provokes. Observe for at least 24 hours after the last octreotide dose (longer for chlorpropamide or kidney failure).
- Insulin overdose: supportive dextrose, potassium replacement (insulin drives potassium intracellularly), and prolonged observation for depot insulin.
- Treat the cause: hydrocortisone for adrenal crisis, thiamine before glucose in possible Wernicke risk, and stop offending drugs.
Warning
Give thiamine 100 to 500 mg IV to malnourished or alcohol-dependent patients when administering glucose. The acute carbohydrate load can precipitate Wernicke encephalopathy in thiamine deficiency.
Pitfalls
- Treating the number rather than the patient: a single capillary value in shock should be confirmed.
- Dialysis and CRRT: the glucose content of the dialysate or replacement fluid changes insulin needs. Glucose-free solutions cause hypoglycemia, and citrate and lactate loads add calories.
- Steroid tapers: insulin needs can halve within hours of stopping high-dose steroids.
- Enteral feed interruption: for procedures, reduce or stop short-acting insulin and start dextrose-containing fluid.
- Hyperkalemia treatment: after insulin plus dextrose, hypoglycemia occurs commonly within 1 to 3 hours, especially in kidney failure. Check glucose for several hours.
- Relative hypoglycemia: a patient whose usual glucose is 250 mg/dL may be symptomatic at 90 mg/dL. Lower chronic hyperglycemia gradually.
A 68-year-old woman in the medical ICU with pneumonia and septic shock has a glucose of 232 mg/dL on three consecutive measurements. She is receiving continuous enteral nutrition. According to current critical care guidance, which approach is most appropriate?
Start an intravenous insulin infusion targeting 81 to 108 mg/dL for the lowest infection risk
Start an intravenous insulin infusion targeting roughly 140 to 180 mg/dL
Withhold insulin until glucose exceeds 250 mg/dL to avoid any risk of hypoglycemia
Give sliding-scale subcutaneous insulin only when glucose exceeds 300 mg/dL
A 79-year-old man with chronic kidney disease taking glipizide is brought in with a glucose of 28 mg/dL and confusion. He improves after 50 mL of dextrose 50%, but becomes hypoglycemic again twice over the next 3 hours despite a dextrose 10% infusion. What is the most appropriate addition to his management?
Subcutaneous octreotide 50 to 100 micrograms every 6 to 12 hours
Intramuscular glucagon 1 mg every 4 hours as needed
Intravenous hydrocortisone 100 mg every 8 hours
Switch to a dextrose 5% infusion to avoid rebound hyperinsulinemia
A 54-year-old man with alcohol use disorder, poor oral intake for a week, and a glucose of 32 mg/dL has no intravenous access on arrival. While access is being obtained, which intervention carries the greatest risk of failing in this patient?
Intramuscular glucagon 1 mg, because hepatic glycogen stores are likely depleted
Oral glucose gel applied to the buccal mucosa after the airway is assessed
Intraosseous dextrose 10% infusion in the proximal tibia
Intravenous thiamine given before dextrose once access is available
Sections you finish are checked off in the contents.